• Anna Luisa Kühn, Matthew J Gounis, and Ajit S Puri.
• Division of Neuroradiology, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
• Neurosurgery. 2020 Jan 1; 86 (Suppl 1): S3-S10.

AbstractThe introduction of flow diverter technology to the field of neurointervention has revolutionized the treatment of intracranial aneurysms. The therapy approach has shifted from intrasaccular aneurysm treatment to exclusion of the aneurysm from the blood circulation with remodeling of the parent artery. Previously, "difficult"-to-treat aneurysms including fusiform and blister aneurysms, but also aneurysms arising from a diseased vessel segment, can now be safely and permanently treated with flow diverters.  A little over a decade ago, after extensive bench testing and refinement of the flow diverter concept, the device was eventually available for clinical use and today it has become a standard treatment for intracranial aneurysms. Currently, United States Food and Drug Administration (FDA)-approved flow diverters are the Pipeline Embolization Device (Medtronic) and the Surpass Streamline Flow Diverter (Stryker).  The devices can either be delivered or deployed via a standard femoral artery approach or a radial artery approach. Other considerations for catheter setup and device deployment strategies depending on aneurysm location or vessel anatomy are described.Copyright © 2019 by the Congress of Neurological Surgeons.

15 keywords...

hide…